アジア太平洋の免疫抑制薬市場予測2019-2028

◆英語タイトル:ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028
◆商品コード:INK20AG131
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年1月
◆ページ数:104
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥130,000見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥156,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe Asia Pacific immunosuppressant drugs market is projected to register a CAGR of 5.51% during the forecast period, 2019-2028. The rising per capita income in several countries of the region, government initiatives for the enhancement of the healthcare sector, the presence of leading manufacturers, and their activities for extending geographical presence, are the most important factors driving the market growth.

MARKET INSIGHTS
The Asia Pacific immunosuppressant drugs market growth analysis encompasses the market evaluation of Japan, Indonesia, China, Thailand, Vietnam, India, Australia & New Zealand, South Korea, and the rest of Asia Pacific. There is a growing demand for organ translation, and a rise in autoimmune diseases like irritable bowel syndrome and arthritis, which impacts market growth in the region. In Japan, the drugs for immunosuppressive agents and diabetes are registering strong growth, and is set to witness more growth propelled by novel biologics. India has placed itself in a prominent position in global pharmaceuticals. It is a major contributor to generic medicines globally, ranking third in the world for production by volume. The country accounts for almost 15% of the world’s production by value. The country houses more than 3000 pharma companies, along with being home to several autoimmune diseases. India has an emboldened living kidney transplantation program, second to the USA. Such factors make the country a conducive market in terms of growth prospects.

COMPETITIVE INSIGHTS
Some of the well-established companies of the market include, Sanofi SA, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Pfizer Inc, Mylan NV, Novartis International Ag (Sandoz), etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
3.3.2. RISE IN ORGAN TRANSPLANTATION
3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
3.4. KEY RESTRAINTS
3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
5. MARKET BY DISTRIBUTION CHANNEL
5.1. HOSPITAL PHARMACIES
5.2. RETAIL PHARMACIES
5.3. ONLINE PHARMACIES
6. MARKET BY END-USER
6.1. ORGAN TRANSPLANTATION
6.2. AUTOIMMUNE DISORDERS
6.3. OTHERS
7. MARKET BY DRUG CLASS
7.1. CORTICOSTEROIDS
7.2. MONOCLONAL ANTIBODIES
7.3. CALCINEURIN INHIBITORS
7.4. MTOR INHIBITORS
7.5. OTHERS
8. GEOGRAPHICAL ANALYSIS
8.1. ASIA PACIFIC
8.1.1. CHINA
8.1.2. JAPAN
8.1.3. INDIA
8.1.4. SOUTH KOREA
8.1.5. INDONESIA
8.1.6. THAILAND
8.1.7. VIETNAM
8.1.8. AUSTRALIA & NEW ZEALAND
8.1.9. REST OF ASIA PACIFIC
9. COMPANY PROFILES
9.1. ABBVIE INC
9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
9.3. ASTELLAS PHARMA INC
9.4. BRISTOL-MYERS SQUIBB COMPANY
9.5. CIPLA LTD
9.6. DR. REDDY’S LABORATORIES LTD
9.7. F HOFFMANN-LA ROCHE AG
9.8. GLAXOSMITHKLINE PLC
9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
9.11. MYLAN NV
9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
9.13. PFIZER INC
9.14. SANOFI SA
9.15. VELOXIS PHARMACEUTICALS

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 4: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 8: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 10: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アジア太平洋の免疫抑制薬市場予測2019-2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆